0001225208-23-011072.txt : 20231213
0001225208-23-011072.hdr.sgml : 20231213
20231213190446
ACCESSION NUMBER: 0001225208-23-011072
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231213
FILED AS OF DATE: 20231213
DATE AS OF CHANGE: 20231213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUSSALLEM MICHAEL A
CENTRAL INDEX KEY: 0001204551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 231485234
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES CORP
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0508
4
2023-12-13
0001099800
Edwards Lifesciences Corp
EW
0001204551
MUSSALLEM MICHAEL A
ONE EDWARDS WAY
IRVINE
CA
92614
1
1
Common Stock
2023-12-13
4
M
0
29350.0000
36.7500
A
33835.8200
D
Common Stock
2023-12-13
4
S
0
1828.0000
75.7300
D
32007.8200
D
Common Stock
2023-12-13
4
S
0
3200.0000
73.1500
D
28807.8200
D
Common Stock
2023-12-13
4
S
0
10600.0000
74.2200
D
18207.8200
D
Common Stock
2023-12-13
4
S
0
13722.0000
75.1200
D
4485.8200
D
Common Stock
4038377.0000
I
By Living Trust
Employee Stock Option (Right to Acquire)
36.7500
2023-12-13
4
M
0
29350.0000
0.0000
D
2017-06-11
2024-05-10
Common Stock
29350.0000
146750.0000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
This transaction was executed in multiple trades at prices ranging from $75.560 to $75.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $72.510 to $73.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $73.520 to $74.515. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $74.530 to $75.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2023-12-13